2. Search Result
Search Result
Isoforms Recommended: CYP17A1
Results for "

CYP17A1

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

3

Isotope-Labeled Compounds

4

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-70013
    Abiraterone
    Maximum Cited Publications
    24 Publications Verification

    CB-7598

    		 Cytochrome P450 Cancer
    Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    Abiraterone
  • HY-75054
    Abiraterone acetate
    20+ Cited Publications

    CB7630

    		 Cytochrome P450 Cancer
    Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    Abiraterone acetate
  • HY-B0105B
    Levoketoconazole
    1 Publications Verification

    (-)-Ketoconazole; (-)-Ketoconazol; (-)-R 41400

    		 Cytochrome P450 Infection Inflammation/Immunology
    Levoketoconazole ((-)-Ketoconazole) is the 2S,4R enantiomer derived from racemic Ketoconazole (HY-B0105). Levoketoconazole is a potent and orally active cortisol synthesis inhibitor. Levoketoconazole inhibits key steps in cortisol and testosterone synthesis by inhibiting CYP11B1, CYP11A1, and CYP17A1. Levoketoconazole can be used for research on endogenous Cushing’s syndrome .
    Levoketoconazole
  • HY-70013S
    Abiraterone-d4

    CB-7598-d4

    		 Cytochrome P450 Cancer
    Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    Abiraterone-d4
  • HY-109619
    D4-abiraterone

    Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite

    		 Androgen Receptor Cytochrome P450 Cancer
    D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.
    D4-abiraterone
  • HY-W073128
    Perfluorotetradecanoic acid

    PFTeDA

    		 PPAR Apoptosis PGC-1α AMPK Akt mTOR Reactive Oxygen Species (ROS) Endocrinology
    Perfluorotetradecanoic acid (PFTeDA) is an orally active perfluoroalkyl substance. Perfluorotetradecanoic acid directly binds to the ligand-binding domain of purified hPPARγ, with a Kd value of 157.8 μM. Perfluorotetradecanoic acid significantly reduces the activity of the SIRT1/PGC1α and AMPK signaling pathways while stimulating the activity of the AKT1/mTOR signaling pathway. Perfluorotetradecanoic acid significantly upregulates the expression of corticosterone biosynthesis genes. Perfluorotetradecanoic acid increases ROS levels and promotes Apoptosis. Perfluorotetradecanoic acid impairs Leydig cell function and male reproductive endocrine function in adult male rats .
    Perfluorotetradecanoic acid
  • HY-75054R
    Abiraterone acetate (Standard)
    20+ Cited Publications

    CB7630 (Standard)

    		 Reference Standards Cytochrome P450 Cancer
    Abiraterone acetate (Standard) is the analytical standard of Abiraterone acetate. This product is intended for research and analytical applications. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    Abiraterone acetate (Standard)
  • HY-W741510
    21-Deoxy cortisone

    21-Desoxycortisone; NSC 38722

    		 Endogenous Metabolite Cardiovascular Disease
    21-Deoxy Cortisone (21-Desoxycortisone; NSC 38722) is a corticosteroid metabolite of 11-ketoprogesterone. It is formed from 11-ketoprogesterone by the cytochrome P450 (CYP) isozyme CYP17A1, but can also be produced by oxidation of 21-deoxycortisone (HY-113405) by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Congenital adrenal hyperplasia is an inborn error of metabolism characterized by a deficiency of 21-hydroxylase, and 21-Deoxy Cortisone levels are elevated in patients with congenital adrenal hyperplasia.
    21-Deoxy cortisone
  • HY-148375
    Abiraterone sulfate

    		Drug Metabolite Others
    Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
    Abiraterone sulfate
  • HY-103687
    Abiraterone metabolite 1

    3β-OH-5α-Abi

    		 Drug Metabolite Cancer
    Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.
    Abiraterone metabolite 1
  • HY-116643
    SU 10603

    		Cytochrome P450 Metabolic Disease
    SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1) .
    SU 10603
  • HY-RS03437
    CYP17A1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CYP17A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP17A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP17A1 Human Pre-designed siRNA Set A
    CYP17A1 Human Pre-designed siRNA Set A
  • HY-137193
    5,6-Dihydroabiraterone

    		Drug Metabolite Cancer
    5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .
    5,6-Dihydroabiraterone
  • HY-RS17785
    Cyp17a1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp17a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cyp17a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp17a1 Mouse Pre-designed siRNA Set A
    Cyp17a1 Mouse Pre-designed siRNA Set A
  • HY-RS24252
    Cyp17a1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp17a1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cyp17a1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp17a1 Rat Pre-designed siRNA Set A
    Cyp17a1 Rat Pre-designed siRNA Set A
  • HY-172173
    CYP17A1-IN-1

    		Cytochrome P450 Cancer
    CYP17A1-IN-1 (Compound 14) is the inhibitor for CYP17A1 with an IC50 of 26 nM. CYP17A1-IN-1 exhibits cytotoxicity in androgen-sensitive prostate cancer cell LNCaP, inhibits the migration of cell DU-145 .
    CYP17A1-IN-1
  • HY-175972
    CAI/II-IN-12

    		Carbonic Anhydrase Neurological Disease Cancer
    CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma .
    CAI/II-IN-12
  • HY-163359
    CYP17A1/HDAC6-IN-1

    		Cytochrome P450 HDAC Cancer
    CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC50 of 0.284μM and 0.6015 μM,respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity .
    CYP17A1/HDAC6-IN-1
  • HY-111421
    ODM-204

    		Androgen Receptor Cytochrome P450 Cancer
    ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC50s of 80 nM and 22 nM, respectively.
    ODM-204
  • HY-181045
    CYP17A1-IN-2

    		Cytochrome P450 Cancer
    CYP17A1-IN-2 is a potent inhibitor of CYP17A1. CYP17A1-IN-2 exhibits anti-proliferative activity against prostate cancer cells. CYP17A1-IN-2 can be used in research related to castration-resistant prostate cancer .
    CYP17A1-IN-2
  • HY-155666
    YXG-158

    		Androgen Receptor Cancer
    YXG-158 (Compound 23-h) is an orally active AR degrader and CYP17A1 inhibitor. YXG-158 has AR degradation activity with DC50 value of 1.28 μM. YXG-158 can inhibit CYP17A1 with IC50 value of 100 nM. XG-158 can be used for the research of enzalutamide-resistant prostate cancer .
    YXG-158
  • HY-117529
    BMS-351

    		Cytochrome P450 Cancer
    BMS-351 (compound 18) is a potent, oral active, nonsteroidal CYP17A1 lyase inhibitor with the IC50 values of 19 nM and 4 nM aganist human CYP17A1 and cynomolgus monkeys CYP17A1,respectively. BMS-351 can be used for the study of castration-resistant prostate cancer .
    BMS-351
  • HY-148376
    Abiraterone N-oxide

    		Drug Metabolite Cancer
    Abiraterone N-oxide is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
    Abiraterone N-oxide
  • HY-164457
    ASN-001

    		Cytochrome P450 Cancer
    ASN-001 is an orally active CYP-17A1 lyase inhibitor that selectively inhibits testosterone synthesis. ASN-001 has anticancer activity and can be used for research in the field of prostate cancer .
    ASN-001
  • HY-137389
    Anhydro abiraterone

    		Drug Metabolite Cancer
    Anhydro abiraterone is a degradation product of Abiraterone acetate (HY-75054). Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity .
    Anhydro abiraterone
  • HY-75054S
    Abiraterone acetate-d4

    CB7630-d4

    		 Isotope-Labeled Compounds Cytochrome P450 Cancer
    Abiraterone acetate-d4 is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    Abiraterone acetate-d4
  • HY-W342082
    11-Ketoprogesterone

    11KP4

    		 11β-HSD Cytochrome P450 Cancer
    11-Ketoprogesterone (11KP4) is the substrate for CYP17A1 and 11β-HSD2 that could be metabolized to 21-deoxycortisone (21dE) and 21-deoxycortisol (21dF) with glucocorticoid activity .
    11-Ketoprogesterone
  • HY-75054S1
    Abiraterone acetate-d3

    CB7630-d3

    		 Isotope-Labeled Compounds Cytochrome P450 Cancer
    Abiraterone acetate-d3 (CB7630-d3) is deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598) .
    Abiraterone acetate-d3
  • HY-W636234
    GSK2636771 methyl

    		PI3K Cancer
    GSK2636771 methyl (compound II) is an inhibitor of PI3Kβ. GSK2636771 methyl can be used in the research of cancer combined with VT-464 (HY-15996) .
    GSK2636771 methyl
  • HY-70013R
    Abiraterone (Standard)

    CB-7598 (Standard)

    		 Reference Standards Cytochrome P450 Cancer
    Abiraterone (Standard) is the analytical standard of Abiraterone. This product is intended for research and analytical applications. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    Abiraterone (Standard)
  • HY-120067
    YM116

    		Cytochrome P450 Endocrinology
    YM116 is an orally active and competitive CYP17A1 (17,20-lyase) inhibitor (Ki: 0.38 nM). YM116 reduces the synthesis of adrenal androgens by preferentially inhibiting C17-20 lyase activity. YM116 decreases the serum testosterone concentration, reduces dehydroepiandrosterone sulfate levels and decreases prostatic weights .
    YM116
  • HY-101516
    CYP17-IN-1

    		Cytochrome P450 Cancer
    CYP17-IN-1 (compound 9c) is a potent and orally active CYP17 inhibitor against rat and human CYP17 with IC50s of 15.8 and 20.1 nM .
    CYP17-IN-1
  • HY-103687R
    Abiraterone metabolite 1 (Standard)

    3β-OH-5α-Abi (Standard)

    		 Reference Standards Drug Metabolite Cancer
    Abiraterone metabolite 1 (Standard) is the analytical standard of Abiraterone metabolite 1. This product is intended for research and analytical applications. Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.
    Abiraterone metabolite 1 (Standard)
  • HY-122744
    CYP11B1-IN-1

    		Cytochrome P450 Metabolic Disease Cancer
    CYP11B1-IN-1 (Compound 25) is a selective, orally active hCYP11B1 inhibitor, with an IC50 of 2 nM against hCYP11B1 and an IC50 of 1.8 μM against rat CYP11B1. CYP11B1-IN-1 can be used for the research of Cushing's disease .
    CYP11B1-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: